The global Biomarker
Research Services Market by Service Type (Biomarker Research Services, and
CDx Research Services), By Disease Indication (Oncology, Cardiovascular
Disorder, Infectious Disease, Neurological Disorder, Immunological Disorder,
and Others), By End User (Hospitals, Specialty Clinics, and Diagnostic
Centers), and By Region (North America, Latin America, Europe, Asia Pacific,
the Middle East, and Africa) was valued at US$ 5,897.7 million in 2017 and is
projected to exhibit a CAGR of 13.5% over the forecast period (2018–2026).
The global biomarker research
services market is expected to witness significant growth over the forecast
period, owing to factors such as collaborations and partnerships, mergers and
acquisitions, and product launches. Furthermore, factors such as increasing
application of biomarkers, and increasing use of companion diagnostics for
personalized medicine is expected to fuel growth of the global biomarker
research services market. In May 2019, BioIVT joined the Foundation for the
National Institutes of Health (FNIH) Biomarkers Consortium. The FNIH Biomarkers
Consortium is a public-private biomedical research partnership. It brings
together members of industry, academia, nonprofit and patient advocacy
organizations, and government agencies and institutes to develop and support
research to qualify promising biomarkers for disease diagnosis, predicting
therapeutic response, and improving clinical practice. Moreover, in 2017,
BioIVT acquired Asterand Bioscience, a global provider of high quality,
well-characterized human tissue, and research solutions, with a focus on the
oncology market. Asterand Bioscience is focused on drug research by
accelerating target identification and biomarker validation and improving drug
candidate selection to increase the likelihood of clinical success.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/biomarker-research-services-market-2612
Browse 26 Market Data Tables and
32 Figures spread through 178 Pages and in-depth TOC on Global Biomarker
Research Services Market by Service Type (Biomarker Research Services, and CDx
Research Services), By Disease Indication (Oncology, Cardiovascular Disorder,
Infectious Disease, Neurological Disorder, Immunological Disorder, and Others),
By End User (Hospitals, Specialty Clinics, and Diagnostic Centers) and By
Region (North America, Latin America, Europe, Asia Pacific, the Middle East,
and Africa) - Global Forecast to 2026
In 2017, REPROCELL Corporation
formed an alliance with Fox Chase Medical Center (Philadelphia, U.S.) to
accelerate biomarker and genetic discovery. Through this alliance, REPROCELL
Corporation focused on augmenting its global repository of bio-specimens with
samples from the Fox Chase Cancer Center and ensured that researchers had access
to a wide array of clinical-grade bio-specimens. Moreover, in 2017,
Bristol-Myers Squibb Company and Nordic Bioscience A/S announced a
collaboration agreement to develop biomarker technology to potentially aid the
diagnosis and monitoring of fibrotic diseases including non-alcoholic
steatohepatitis (NASH). In 2017, Nordic Bioscience S/A received CE marking for
its PRO-C3 assay. This is part of the company’s regulatory efforts to support
biomarker use in clinical research. The marking signifies that the measurement
of PRO-C3 is of high quality, and is controlled in an appropriate manner.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2612
Key Takeaways of the Global Biomarker
Research Services Market:
The global biomarker research
services market is expected to exhibit a CAGR of 5% over the forecast period (2018–2026),
owing to rising prevalence of diseases and rising need for early diagnosis. For
instance, according to National Cancer Institute, 2016, an estimated 16.8
million new cases of cancer were diagnosed in the U.S. with around 595,690
deaths from the disease. The number of people with cancer is expected to
increase up to 19 million by 2024.
Manufacturers are focused on
employing contract research organizations for research and development of
biomarkers, which is expected to aid the market growth over the forecast
period.
Companion diagnostic research
services are expected to witness significant growth over the forecast period
Major players operating in the
global biomarker research services market include Noble Life Sciences, Inc.,
Reprocell Corporation, Coriell Institute, BioIVT, ICON Plc., SRI International,
Inc., Charles River Laboratories, Inc., Nordic Bioscience A/S, Proteome
Sciences Plc., and Covance Inc. (Laboratory Corporation of America Holdings,
Inc.)
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2612
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment